August 29th Posting On Three Articles About Multiple Sclerosis

M.S. Trial Alert: Investigators Recruiting for Study of Tysabri in Early Relapsing-Remitting M.S.

U.S. officials are enlisting 300 individuals with early relapsing-remitting Multiple Sclerosis to find different reasons that will possibly develop this stage of M.S. The individuals have already began the treatment on Tysabri and are not taking any other drug for this study. In this observational study, the persons that are getting observed have had relapsing-remitting M.S. for at least three years and who have made the choice themselves to take Tysabri. This study is also known as the STRIVE study and is supported by Biogen, Idec.
http://www.nationalmssociety.org/research/research-news/index.aspx

New Studies focus on Vitamin D and M.S.

A number of innate and ecological stimuli affects whether a person will get Multiple Sclerosis. These countless elements may also influence the harshness of this illness. Examination shows that a reduced level of Vitamin D in the blood is a conceivable danger factor for acquiring M.S. In lab mice, Vitamin D can reduce the effects of EAE, which is an M.S. like illness, and growing evidence suggests it is time to experiment if Vitamin D can implement assistance to the individuals that suffer from this terminal disease.
http://www.nationalmssociety.org/research/research-news/news-detail/index.aspx?nid=6706

Study suggests that interferon’s did not decrease M.S progression.

In a study done on over 2,000 patients in British Columbia, individuals enrolled in M.S. treatment centers are said to have no reduction of advancement of M.S. when given interferon’s for their disease. This was equated alongside people who were not treated with the interferon beta drug. M.S. comprises the immune system assaults against the brain and the spinal cord. While the results are still continuing, the examination did not address the value of interferon beta in reducing M.S. reversions and the development of lesions. 
http://www.nationalmssociety.org/research/research-news/news-detail/index.aspx?nid=6640